Xencor (NASDAQ:XNCR) Rating Lowered to “Sell” at StockNews.com

Xencor (NASDAQ:XNCR) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a note issued to investors on Friday.

Other analysts also recently issued reports about the company. Wells Fargo & Company cut their target price on Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a research note on Friday, February 28th. Piper Sandler upgraded shares of Xencor from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $20.00 to $30.00 in a research report on Monday, December 2nd. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $34.38.

Xencor Stock Performance

XNCR opened at $12.76 on Friday. Xencor has a twelve month low of $12.69 and a twelve month high of $27.24. The firm has a market capitalization of $899.10 million, a PE ratio of -3.99 and a beta of 0.74. The company has a current ratio of 6.23, a quick ratio of 6.23 and a debt-to-equity ratio of 0.01. The firm’s 50-day moving average price is $17.36 and its 200 day moving average price is $20.44.

Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.62) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.19. Xencor had a negative return on equity of 30.92% and a negative net margin of 232.77%. The business had revenue of $52.79 million for the quarter, compared to analysts’ expectations of $17.14 million. As a group, sell-side analysts expect that Xencor will post -3.68 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Mackenzie Financial Corp acquired a new position in shares of Xencor in the 4th quarter worth approximately $101,000. GF Fund Management CO. LTD. acquired a new position in Xencor during the fourth quarter worth $34,000. Public Employees Retirement System of Ohio purchased a new position in shares of Xencor during the fourth quarter worth $1,227,000. Woodline Partners LP grew its stake in shares of Xencor by 0.3% in the fourth quarter. Woodline Partners LP now owns 845,916 shares of the biopharmaceutical company’s stock valued at $19,439,000 after buying an additional 2,591 shares in the last quarter. Finally, Teza Capital Management LLC purchased a new stake in shares of Xencor in the 4th quarter valued at $210,000.

Xencor Company Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.